113 related articles for article (PubMed ID: 17068390)
1. Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease.
Bergner R; Diel IJ; Henrich D; Hoffmann M; Uppenkamp M
Onkologie; 2006 Nov; 29(11):534-40. PubMed ID: 17068390
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of intravenous bisphosphonates.
Mehrotra B
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S24-7. PubMed ID: 18068487
[TBL] [Abstract][Full Text] [Related]
3. Adverse effects of bisphosphonates: current issues.
Diel IJ; Bergner R; Grötz KA
J Support Oncol; 2007; 5(10):475-82. PubMed ID: 18240669
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate treatment recommendations for oncologists.
von Moos R
Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
[TBL] [Abstract][Full Text] [Related]
5. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
6. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
Conte P; Guarneri V
Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate nephrotoxicity.
Perazella MA; Markowitz GS
Kidney Int; 2008 Dec; 74(11):1385-93. PubMed ID: 18685574
[TBL] [Abstract][Full Text] [Related]
8. Taking the lead: sharing best practice in intravenous bisphosphonate use in urological cancers.
Jensen BT; Dielenseger P; Drudge-Coates L; Flynn K; Hieronymi S; Erik van Muilekom HA; Pieters R; Voss LB
Eur J Oncol Nurs; 2012 Feb; 16(1):42-53. PubMed ID: 21429796
[TBL] [Abstract][Full Text] [Related]
9. Preclinical perspectives on bisphosphonate renal safety.
Body JJ; Pfister T; Bauss F
Oncologist; 2005; 10 Suppl 1():3-7. PubMed ID: 16264106
[TBL] [Abstract][Full Text] [Related]
10. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
11. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review.
Miller PD; Ward P; Pfister T; Leigh C; Body JJ
Clin Exp Rheumatol; 2008; 26(6):1125-33. PubMed ID: 19210886
[TBL] [Abstract][Full Text] [Related]
12. Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases.
Luedders DW; Steinhoff J; Thill M; Rody A; Bohlmann MK
Anticancer Res; 2015 Mar; 35(3):1797-802. PubMed ID: 25750345
[TBL] [Abstract][Full Text] [Related]
13. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results.
Body JJ; Diel IJ; Tripathy D; Bergstrom B
Eur J Cancer Care (Engl); 2006 Jul; 15(3):299-302. PubMed ID: 16882128
[TBL] [Abstract][Full Text] [Related]
14. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
Pecherstorfer M; Diel IJ
Support Care Cancer; 2004 Dec; 12(12):877-81. PubMed ID: 15372222
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
Kotteas E; Alamara C; Kiagia M; Pantazopoulos K; Boufas A; Provata A; Charpidou A; Syrigos KN
Anticancer Res; 2008; 28(1B):529-33. PubMed ID: 18383897
[TBL] [Abstract][Full Text] [Related]
17. The kidney and bisphosphonates.
Miller PD
Bone; 2011 Jul; 49(1):77-81. PubMed ID: 21232648
[TBL] [Abstract][Full Text] [Related]
18. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
19. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
Weide R; Koppler H; Antras L; Smith M; Chang MP; Green J; Wintfeld N; Neary MP; Duh MS
J Cancer Res Ther; 2010; 6(1):31-5. PubMed ID: 20479544
[TBL] [Abstract][Full Text] [Related]
20. Renal safety of ibandronate.
Jackson GH
Oncologist; 2005; 10 Suppl 1():14-8. PubMed ID: 16264108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
